Bacillus Calmette-Gu érin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiscussionIt is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic.Trial registrationClinicalTrials.gov NCT04348370. Registered on April 16, 2020.
Source: Trials - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Brain | Covid Vaccine | COVID-19 | Diabetes | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Health Management | Hospitals | Hypertension | Neurology | Obesity | Opthalmology | Research | Respiratory Medicine | SARS | Smokers | Study | Teachers | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines | Veterinary Research | Veterinary Vaccinations